Tazarotene

Biological Activity

Receptor-selective acetylenic retinoid; binds at retinoid acid receptors (RAR) -β and -γ. Topically used for the treatment of skin disorders, particularly psoriasis and acne. Implicated in the treatment of basal cell carcinomas; induces upregulation of Bax in vivo. Exhibits antiproliferative and proapoptotic activity. Upregulates TIGs (Tazarotene-induced genes), including the cell adhesion molecule TIG1 and the tumor-suppressor TIG3.

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Background References

1. Induction of TIG3, a putative class II tumor suppressor gene, by retinoic acid in head and neck and lungcarcinoma cells and its association with suppression of the transformed phenotype.
   Higuchi et al.
   Oncogene, 2003;22:4627
2. Expression and mutation analysis of TIG1 (Tazarotene-induced gene 1) in human gastric cancer.
   Son et al.
   Oncol.Res., 2009;17:571
3. Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazar.
   Orlandi et al.
   J.Invest.Dermatol., 2004;122:1037

Product Datasheets